| Q69185943 | Clinical and Laboratory Findings in a Trial of Norgestrel, a Low-dose Progestogen-only Contraceptive |
| Q67289818 | Contraception with a norethisterone-releasing IUD. Plasma levels of norethisterone and its influence on the ovarian function |
| Q42005103 | Contraception with megestrol acetate implants. Megestrol acetate levels in plasma and the influence on the ovarian function |
| Q39713270 | Contraception — retrospect and prospect |
| Q46636729 | Effect of Norplant implants on the pituitary-adrenal axis function and reserve capacity |
| Q44657940 | Effect of norgestrel administered intermittently on pituitary ovarian function |
| Q67812479 | Effects of intranasal administration of norethisterone on folliculogenesis, cervical mucus, vaginal cytology, endometrial morphology and reproductive-endocrine profile in women |
| Q43655406 | Gestagens and progesterone production. |
| Q72796940 | Inhibition of 3-beta-hydroxy steroid dehydrogenase activity in first trimester human pregnancy with trilostane and WIN 32729 |
| Q66943316 | Lack of clinical contraceptive efficacy of large doses of R 2323 given before implantation or after a missed period |
| Q40818679 | Ovulation inhibition by a new low-dose progestagen |
| Q44804920 | Plasma levels of d-norgestrel, estradiol and progesterone during treatment with silastic implants containing d-norgestrel |
| Q69410594 | Postovulatory contraception in women with large doses of norethindrone |
| Q39869889 | Progestagen-only oral contraceptives: a preliminary report of the action and clinical use of norgestrel and norethisterone |
| Q64113507 | RANDOMISED DOUBLE-BLIND TRIAL OF FOUR ORAL PROGESTAGEN-ONLY CONTRACEPTIVES |
| Q42448326 | Studies on the Mechanism of Action of Continuous Microdose Quingestanol Acetate |
| Q39788689 | The effect of synthetic gestagens on progesterone formation in vitro in human corpus luteum of early pregnancy |
| Q48487577 | Urinary Hormone Excretion Patterns during Low-Dose Progestogen Administration |